The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with ...
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
Congress and regulating agencies including the FTC and HHS scrutinized PBM business practices and ... Expansion into the supply chain side of the drug industry is seen through investments like ...
Yet, perhaps the most significant healthcare reforms in the stopgap funding bill released late Tuesday are changes to how controversial middlemen in the drug supply ... on the PBM’s formulary.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback